Cutting-Edge Specialty Meets Cutting-Edge Review.

wcg Oncology™

Every year, nearly 14 million people around the world learn that they have cancer. Another eight million people die from the disease, according to the Centers for Disease Control.

As partners in the mission to find a cure, the WIRB-Copernicus Group® (WCG) has created **WCG Oncology™**, a comprehensive solution that enables the highest quality review of cancer research while protecting the rights of its participants.

WCG Oncology

At WCG, we have the utmost compassion for patients and families facing a cancer diagnosis. And we understand the unique ethical challenges faced by investigators and coordinators in the conduct of oncology trials.

That's why we created WCG Oncology. It is our role to protect the well-being of research participants while helping to advance medical research. We combine our unmatched expertise in regulatory and ethical oversight with the insights of the leaders in oncology research to deliver a precise, thorough review of clinical trials in oncology.

Oncology Reviews

Distribution of oncology protocols by sub-specialty



- 23% Hematologic
- 14% Breast
- 13% Lung
- 9% Mixed
- 6% Prostate
- 6% Melanoma
- 5% Pancreas
- 5% GYN
- 3% Liver
- 3% Colorectal
- 3% Renal/Kidney/Bladder
- 3% Giloma/GBM

OTHER 7%:

- Head/Neck
- Sarcoma
- Other Squamous Cell
- Carcinoid
- Thyroid
- Device/Diagnostic
- Ancillary/Supportive
- PK/PD
- Gastroesophageal

WCG reviews more oncology protocols than any other solution provider.

Experts

AN ADVISORY BOARD OF VISIONARIES AND THOUGHT LEADERS in oncology that provide guidance and strategic counsel on the changing landscape of research in oncology.

A PANEL OF EXPERT CONSULTANTS, each of whom is deeply knowledgeable in a specific oncological discipline or area of research, to assist in the review of complex and scientifically challenging research.

THREE DEDICATED, EXPERIENCED REVIEW PANELS focused wholly on the ethical and regulatory oversight of research in oncology.

Advisory Board



George Demetri, MD
Dana-Farber Cancer Institute

John M. Falletta, MD
Duke University Medical Center

Arnold J. Levine, PhD
Institute for Advanced Study,
School of Natural Sciences

John E. Niederhuber, MD
Inova Translational
Medicine Institute,
Former Head of the National
Cancer Institute

James Rothman, PhD
Yale University; Recipient, Nobel
Prize in Medicine, 2013

Howard Scher, MD
Memorial Sloan Kettering
Cancer Center

The Only Single

In addition to the unique scientific understanding we bring to the oversight of oncology research, we have developed an innovative process to streamline clinical review.
We call it the Single Review Solution™ (SRS).

- **SRS will save you time and money by eliminating the redundancies and administrative delays that plague clinical study start-up.**
- **WCG is the only ethical solutions provider in the world to offer a unified review for all sites involved in a clinical trial.**
- **Whether sites are private, central or institutionally based, each is reviewed under one IRB umbrella using WCG's proprietary SRS process.**
- **SRS connects WCG's industry clients with over 2,300 academic medical centers, universities and hospitals for which WIRB is an IRB of record. Using our central site review process, WCG provides a single, seamless review of the protocol and its associated sites and documentation.**

Our investigator database is the largest in the United States, providing critical metrics for research sites in the therapeutic areas you are targeting.

In the course of our oversight, we have amassed performance data on over 38,000 of the approximately 40,000 FDA-regulated principal investigators in the United States, and over 2,300 institutions in North America. These data are powerful; they enable us to help you find the most efficient research sites and highest performing investigators in every area of clinical research concentration.

SRS leverages the members of the WCG family of companies to deliver increased efficiency in its review of clinical trials.

THE WCG FAMILY OF IRBs

WIRB®
A WIRB-Copernicus Group Company

Review Solution

SRS: The "New Standard" for Oncology IRB Review

Since its launch in 2013, SRS has become the default central IRB solution for the leading sponsors and CROs dedicated to oncology research.



TRADITIONAL APPROACH
4-6 MONTHS COLLECTIVE APPROVAL

SINGLE REVIEW SOLUTION
<8 DAYS COLLECTIVE APPROVAL

copernicus group independent review board
A WIRB-Copernicus Group Company

Midlands Independent Review Board
A WIRB-Copernicus Group Company

Aspireirb
A WIRB-Copernicus Group Company

New England IRB
A WIRB-Copernicus Group Company

The Gold Standard in IBC

As gene transfer research programs progress into late-stage clinical development, researchers find themselves navigating unchartered territory in the realm of biosafety. So the need for a comprehensive biosafety program, anchored by a reliable and compliant Institutional Biosafety Committee (IBC), is more essential than ever. In fact, studies conducted with human gene transfer products that have received any NIH funding are *required* to be reviewed by an IBC.

The most experienced and trusted provider of biosafety solutions, WCG Biosafety™ has more than 15 years of experience in the management and centralized administration of local site IBC review. Since 2001, WCG's IBC Services has been the unrivaled leader in IBC administration. Over sixteen years — and 3,500 convened IBC meetings globally — WCG IBC Services has administered IBCs for over 570 institutions, reviewed over 305 human gene transfer clinical trials and 27 bench research projects (more than any organization outside of the FDA and the NIH).

Review for Gene Therapy

"We are thankful to have found a committed and reliable partner in WCG Biosafety. The team is committed to our success and provides us with invaluable support in navigating this complicated environment, while engaging with us as an advisor, mentor, administrator and collaborator in operating our Institutional Biosafety Committee."

– Nadine Nemunaitis
VP of Research Operations, Mary Crowley Cancer Research Center

At WCG, we understand the unique ethical challenges faced by investigators and coordinators in the conduct of oncology trials.

WCG Oncology provides a deeper level of support to researchers around the world in their mission to eradicate cancer.

Together with our partners in oncology research and cancer care, we will accelerate advancements in oncology research and – one day – **find a cure.**

WIRB-COPERNICUS GROUP

Ingenuity Lives Here

www.wcgclinical.com